Earnings Preview: Novartis still growing in Diovan generics drought
This article was originally published in Scrip
Executive Summary
Novartis is to report first-quarter earnings on 24 April, with analysts expecting it to report EPS of $1.28 on revenue of $14 billion, up from $1.27 and $13.7 billion respectively in the first quarter of 2012. The firm will benefit from the ongoing delay in the arrival of US generic competition to its blockbuster Diovan.